Conversion to belatacept-based immunosuppression therapy in renal transplant patients

Transplantation Proceedings

Volumn 46, Issue 9, 2014, Pages 2987-2990

  Paz, M ^a   Roberti, J ^b   Mos, F ^a   Cicora, F ^a,b  

^a HOSPITAL ALEMÁN   (Argentina)

^b Foundation for Research and Assistance to Renal Disease (FINAER)   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; HLA ANTIBODY; HLA ANTIGEN CLASS 2; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; ABATACEPT; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS;

ACUTE GRAFT REJECTION; ADULT; AGED; ATROPHY; CADAVER DONOR; CLINICAL ARTICLE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULOPATHY; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEG EDEMA; LIVING DONOR; MAINTENANCE THERAPY; MALE; MEDICAL HISTORY; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT INFECTION; VASCULAR LESION; CASE REPORT; GRAFT REJECTION; HUMANS;

ADULT; AGED; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84927624767     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.07.003     Document Type: Conference Paper

References (19)

1. Nankivell BJ, Alexander SI Rejection of the kidney allograft. N Engl J Med 2010; 363:1451-62.
2. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov 2011; 10:655-6.
3. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91: 1057-64.
4. Kaplan B. Belatacept: the promises and challenges of belatacept and costimulatory blockade. Am J Transplant 2010; 10:441-2.
5. Ippoliti G, D'Armini AM, Lucioni M, Marjieh M., Viganò M. Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection. Biologics 2012; 6: 355-62.
6. Vincenti F. Beyond belatacept: praise and progress for the FDA. Am J Transplant Mar 2012; 12:513-4.
7. Rostaing L, Massari P, Garcia V.D., Mancilla-Urrea E, Nainan G, del Carmen Rial M, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6:430-9.
8. Grinyo J, Alberu J, Contieri F.L., Manfro RC, Mondragon G, Nainan G, et al Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int 2012; 25:1059-64.
9. Midtvedt K, Holdaas H. Belatacept: BENEFIT to the kidney? Am J Transpl 2011; 11:633.
10. Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13:2875-83.
11. Cicora F, Paz M, Mos F., Roberti J. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. Case Rep Med 2013; 2013:4-7.
12. Ashman N, Chapagain A, Dobbie H., Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transpl 2008; 9:424-7.
13. Saikali JA, Truong LD, Suki WN Case report sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229-30.
14. Sørensen SS. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transpl 2012; 12:2744-53.
15. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007; 20:813-27.
16. Karthikeyan V, Parasuraman R, Shah V., Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003; 3:1289-94.
17. Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 2012; 25:214-9.
18. Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transpl 2013; 13:2884-91.
19. Grinyó JM, Budde K, Citterio F, Charpentier B. Belatacept utilization recommendations: an expert position. Expert Opin Drug Saf 2013; 12:111-22.